|Bid||39.09 x 2200|
|Ask||39.17 x 3100|
|Day's Range||38.80 - 40.14|
|52 Week Range||27.10 - 50.05|
|Beta (3Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.78|
Yahoo Finance's Julie Hyman highlights today's stocks on the move in midday trading.
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
SAN DIEGO, Calif. , Nov. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences: ...
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Pharmaceutical companies Arena Pharmaceuticals and Sonoma Pharmaceuticals were in the green on Thursday. While Sonoma did not have any news to note, Arena Pharmaceuticals announced that it has entered into a lucrative licensing agreement with United Therapeutics. Arena Pharmaceuticals, Inc. shares were up 22.62% yesterday on around 4.7 million shares traded.
The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment, ralinepag. The two companies said in a statement the deal for Arena's late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018.
- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD - Olorinab positive Phase 2a data for the treatment of pain associated with Crohn's disease; all ...
Jim Cramer said "That train has left the station. In this daily bar chart of ARNA, below, we can see a large sideways trading range with neutral or mixed technical signals. The Moving Average Convergence Divergence (MACD) oscillator recently crossed to the upside from below the zero line - this is a signal to cover shorts.
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update ...
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
If you own shares in Arena Pharmaceuticals Inc (NASDAQ:ARNA) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
SAN DIEGO , Oct. 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a ...
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from ...
SAN DIEGO, Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced positive data from a planned interim analysis of the ongoing open-label extension of the Phase 2 trial of its investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). This is an open-label extension study evaluating the long-term safety, tolerability and efficacy of ralinepag in 45 patients (85% of study completers) who completed the Phase 2 randomized study.